Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Mondelez International
MDLZConsumer StaplesGenerated Aug 19, 2026, 10:33 PM UTC
MDLZ (Mondelez International) analytical snapshot. Revenue grew +5.8% YoY to $38.54B. 5-year revenue CAGR +6.1%; 10y CAGR +4.5%. Net margin at 6.36% (contracting ▼). Market cap $82.36B at $64.16 per share. Trailing P/E 33.95, P/S 2.14, P/B 3.20. EV/Operating income ≈ 26.99 (EV $95.76B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -10 (data confidence 84%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 4, 2026. Latest quarterly report (10-Q) filed Jul 28, 2026. 21 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 4, 2026.
- Latest quarterly report (10-Q) filed Jul 28, 2026.
- 21 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Mondelez International; broad institutional reporting.
- Recent filers include WINNOW WEALTH LLC, UNITED BANK INC /WV/, SOUTHEASTERN ASSET MANAGEMENT INC/TN/.
- 3 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 17 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| WINNOW WEALTH LLC | 13F-HR | Aug 21, 2025 |
| UNITED BANK INC /WV/ | 13F-HR | Jan 23, 2013 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | May 15, 2014 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | Feb 13, 2015 |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 13F-HR | Aug 14, 2014 |
| Date | Form | Description |
|---|---|---|
| Jul 28, 2026 | 8-K | 8-K |
| Jun 18, 2026 | 8-K | 8-K |
| May 26, 2026 | 8-K | 8-K |
| Apr 28, 2026 | 8-K | 8-K |
| Feb 18, 2026 | 8-K | 8-K |
| Feb 3, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Oct 28, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Gross margin compression: Gross margin contracted +10.7%pp (from 39.1% to 28.4%). This may reflect input cost inflation, pricing pressure, or product mix shift toward lower-margin segments.
- Material weakness in internal controls: The term "material weakness" "internal control" appears in 5 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.84x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Goodwill is 34% of total assets: Goodwill of $24.23B represents a large share of the balance sheet. If acquired businesses underperform, a non-cash impairment charge could materially impact earnings. Monitor segment performance and acquisition integration metrics.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 7 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $36.44B | $38.54B | $2.10B | +5.8% |
| Gross profit | $14.26B | $10.94B | $-3.32B | -23.3% |
| Operating income | $6.34B | $3.55B | $-2.80B | -44.1% |
| Net income | $4.61B | $2.45B | $-2.16B | -46.8% |
| Operating cash flow | $4.91B | $4.51B | $-396.0M | -8.1% |
| Capex | $1.39B | $1.28B | $-108.0M | -7.8% |
| Total assets | $68.50B | $71.49B | $2.99B | +4.4% |
| Total liabilities | $41.54B | $45.60B | $4.06B | +9.8% |
| Long-term debt | $15.25B | $15.88B | $625.0M | +4.1% |
| Cash & equivalents | $1.40B | $2.19B | $795.0M | +56.8% |
| Stockholders equity | $26.93B | $25.84B | $-1.09B | -4.1% |
| Inventory | $3.83B | $4.42B | $592.0M | +15.5% |
| Accounts receivable | $3.87B | $3.90B | $29.0M | +0.7% |
| R&D expense | $400.0M | $400.0M | $0 | 0.0% |
| SG&A expense | $7.44B | $7.17B | $-266.0M | -3.6% |
| Interest expense | $508.0M | $599.0M | $91.0M | +17.9% |
| Type | Concepts |
|---|---|
| Added | ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1, ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1, DebtInstrumentFaceAmount, GainLossOnFairValueHedgesRecognizedInEarnings, HedgedLiabilityFairValueHedge, HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease, StockIssuedDuringPeriodValueShareBasedCompensation |
| Removed | AdvertisingExpense, BusinessCombinationAcquisitionRelatedCosts, BusinessCombinationContingentConsiderationLiability, CommonStockCapitalSharesReservedForFutureIssuance, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit, DeferredFederalIncomeTaxExpenseBenefit, DeferredForeignIncomeTaxExpenseBenefit, DeferredIncomeTaxLiabilities |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 5 | 2 | Ongoing |
| Impairment charge | medium | 5 | 8 | Ongoing |
| Restructuring | medium | 5 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 0 | NEW |
| Related party transactions | low | 5 | 0 | NEW |
Fundamentals
Revenue grew +5.8% YoY to $38.54B. 5-year revenue CAGR +6.1%; 10y CAGR +4.5%. Net margin at 6.36% (contracting ▼).
- Revenue grew +5.8% YoY to $38.54B.
- 5-year revenue CAGR +6.1%; 10y CAGR +4.5%.
- Net margin at 6.36% (contracting ▼).
- Return on equity 9.49%, ROA 3.43%, ROIC 13.73%.
- Gross margin 28.38%, operating margin 9.21%.
- Free cash flow margin 8.39% ($3.23B).
- Net income down ▼ +46.8% YoY.
- Debt/equity 0.62, current ratio 0.54, net debt $13.40B.
- Asset turnover 0.54 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $36.44B | +1.2% | 39.12 | 17.41 | 12.65 | $3.52B | 17.12 |
| 2025 | $38.54B | +5.8% | 28.38 | 9.21 | 6.36 | $3.23B | 9.49 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2024 | $8.34B | -1.9% | — | 7.20% |
| Sep 30, 2024 | $9.20B | +1.9% | +10.3% | 9.27% |
| Mar 31, 2025 | $9.31B | +0.2% | +1.2% | 4.32% |
| Jun 30, 2025 | $8.98B | +7.7% | -3.5% | 7.13% |
| Sep 30, 2025 | $9.74B | +5.9% | +8.5% | 7.63% |
| Mar 31, 2026 | $10.08B | +8.2% | +3.4% | 5.56% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $82.36B at $64.16 per share. Trailing P/E 33.95, P/S 2.14, P/B 3.20. EV/Operating income ≈ 26.99 (EV $95.76B).
- Market cap $82.36B at $64.16 per share.
Price & Technicals
Price $64.16 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 55.95.
- Price $64.16 — uptrend (above 200-DMA); 1-month momentum positive.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 0.62 (moderate). Liquidity current ratio 0.54 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -10
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Mondelez International is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewPrice $64.16 — uptrend (above 200-DMA); 1-month momentum positive..
Peer comparison
Defensive groupHow MDLZ stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Zoetis Inc. ZTS | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ● you | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |